180 Life Sciences Corp. Quarterly Operating Income (Loss) in USD from Q4 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
180 Life Sciences Corp. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2016 to Q3 2024.
  • 180 Life Sciences Corp. Operating Income (Loss) for the quarter ending September 30, 2024 was -$979K, a 72.3% increase year-over-year.
  • 180 Life Sciences Corp. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$6.37M, a 63.9% increase year-over-year.
  • 180 Life Sciences Corp. annual Operating Income (Loss) for 2023 was -$13.5M, a 24.7% increase from 2022.
  • 180 Life Sciences Corp. annual Operating Income (Loss) for 2022 was -$17.9M, a 14.4% decline from 2021.
  • 180 Life Sciences Corp. annual Operating Income (Loss) for 2021 was -$15.6M, a 177% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$6.37M -$979K +$2.56M +72.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$8.93M -$1.85M +$1.84M +49.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$10.8M -$2.09M +$2.71M +56.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$13.5M -$1.45M +$4.19M +74.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$17.7M -$3.54M +$517K +12.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$18.2M -$3.68M +$839K +18.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$19M -$4.8M -$1.12M -30.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$17.9M -$5.64M -$1.18M -26.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$16.7M -$4.06M +$162K +3.85% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$16.9M -$4.52M -$509K -12.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-15
Q1 2022 -$16.4M -$3.68M -$733K -24.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$15.6M -$4.46M -$2.05M -84.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$13.6M -$4.22M -$3.49M -477% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$10.1M -$4.01M -$3.08M -330% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$7.03M -$2.95M -$1.38M -88.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$5.65M -$2.42M +$17.7M +88% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$23.3M -$731K -$505K -224% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$22.8M -$934K -$638K -215% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$22.2M -$1.57M -$1.3M -491% Jan 1, 2020 Mar 31, 2020 10-Q 2021-07-19
Q4 2019 -$20.9M -$20.1M -$19.9M -11508% Oct 1, 2019 Dec 31, 2019 10-K 2021-07-09
Q3 2019 -$960K -$226K -$85.4K -60.9% Jul 1, 2019 Sep 30, 2019 10-Q/A 2021-02-05
Q2 2019 -$875K -$296K -$148K -100% Apr 1, 2019 Jun 30, 2019 10-Q/A 2021-02-05
Q1 2019 -$726K -$265K -$127K -92.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-22
Q4 2018 -$599K -$173K -$51.6K -42.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-04-07
Q3 2018 -$547K -$140K +$578 +0.41% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$548K -$148K -$97.5K -193% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$450K -$138K -$107K -341% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 -$344K -$121K -$118K Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$226K -$141K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$50.4K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$31.3K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$3.11K* Sep 7, 2016 Dec 31, 2016 10-K 2018-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.